Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial. (PubMed, Nat Med) - Sep 25, 2026 - P2/3 | "In summary, evo + TRP showed encouraging efficacy with manageable safety in advanced gastric/gastroesophageal junction cancer. ClinicalTrials.gov identifier: NCT05002127 ."
Journal • P2 data • Gastric Cancer • Hematological Disorders • Oncology • Solid Tumor • CD47 • HER-2
|
|
Alison Forgie; Athanasios C Tsiatis; Cherry Mao; Christelle de la Fouchardiere; Clélia Coutzac; Daniel Brickman; Eric Van Cutsem; Jaume Pons; Jeeyun Lee; Josep Tabernero; Keun-Wook Lee; Kohei Shitara; Philip Fanning; Sophia Randolph; Sun Young Rha; Yoon-Koo Kang; Zev Wainberg
|